RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief ...

Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by ...

Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently sold 1,207 shares of the company's common stock. The shares were sold at an average price of $152. ...

Neurocrine Biosciences (NasdaqGS:NBIX) announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...

SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability ...